Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

NCT02031419 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

174

Enrollment

INDUSTRY

Sponsor class

Stopped Replaced with another clinical trial.

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: CC-122
DRUG: CC-223
DRUG: Rituximab
DRUG: CC-122
DRUG: CC-292
DRUG: Rituximab
DRUG: CC-223
DRUG: CC-292
DRUG: Rituximab

Sponsor

Celgene